Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Carisma Therapeutics
HSMN NewsFeed - 26 Mar 2026
Averna Therapeutics Announces Strategic Leadership Expansion
Biopharmaceuticals
Personnel
HSMN NewsFeed - 2 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 14 Jun 2023
Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 27 Jul 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Biopharmaceuticals
Oncology
FDA
HSMN NewsFeed - 3 Jun 2019
Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer
Biopharmaceuticals
Oncology
Personnel
HSMN NewsFeed - 27 Jun 2018
Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
Biopharmaceuticals
Venture Capital
Return to NewsFeed
